Stock Market & Financial Investment News

News Breaks September 20, 2012 08:24 EDT QCOR, AET Questcor Acthar likely to remain reimbursable, says ThinkEquity After Questcor (QCOR) fell sharply on a report suggesting that Aetna (AET) will no longer reimburse doctors who proscribe Questcor's Acthar product, ThinkEquity expects on-label usage of Acthar to ultimately remain reimbursable. The firm maintains a $58 target and Buy rating on Questcor. News For QCOR;AET From The Last 14 Days Check below for free stories on QCOR;AET the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 10:00 EDT AET On The Fly: Analyst Initiation Summary Subscribe for More Information 06:04 EDT AET Aetna reinstated with a Buy at Goldman Target $68. May 15, 2013 17:36 EDT AET Paulson gives quarterly update on stakes Subscribe for More Information 11:20 EDT QCOR Options with increasing implied volatility: QCOR MYGN GDI Subscribe for More Information 05:57 EDT QCOR Stocks with implied volatility movement; SODA QCOR Subscribe for More Information May 14, 2013 12:00 EDT AET Aetna forms strategic alliance with Tawuniya Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.